Life Sciences

  • June 30, 2026

    AIDS Group Says Cigna-Owned Express Scripts Hurts Patients

    AIDS Healthcare Foundation says its nonprofit wellness centers are going to be run out of business if Cigna-owned pharmacy benefit manager Express Scripts isn't stopped from using its muscle in the market to steer pharmacy patients toward specialty pharmacies it's affiliated with.

  • June 30, 2026

    Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims

    A Massachusetts federal judge has permanently dismissed an investor suit alleging Zenas BioPharma hid how quickly it was spending money before its 2024 initial public offering, saying the company warned investors before the IPO that its drug-development costs were high and rising, and therefore did not have to provide a quarter-by-quarter spending breakdown.

  • June 30, 2026

    Cellspin Settles Challenges To Its Patents At PTAB

    Three companies that challenged a series of Cellspin Soft Inc. patents for publishing data on websites have settled their disputes at the Patent Trial and Appeal Board after the board agreed to review the patents earlier this year.

  • June 30, 2026

    Pharma Co. Seeks Injunction Over Chinese Military Co. Label

    Chinese pharmaceutical company WuXi AppTec is urging a D.C. federal court judge to block the Pentagon from enforcing its designation of the company as a "Chinese military company," arguing the listing is unsupported by facts and was imposed without due process.

  • June 30, 2026

    Cigna, Others Fight Ohio AG's Drug Price-Fixing Suit

    Ohio pharmacy benefit managers and their corporate parents urged a federal judge to toss the state's drug price-fixing lawsuit, saying in a series of briefs that the state is trying to skirt federal pleading standards, collapse corporate separateness and stretch Ohio's antitrust law beyond its limits.

  • June 30, 2026

    ResMed Gets PTAB To Ax 1 Out Of 2 Sleep Apnea Patents

    The Patent Trial and Appeal Board has found that ResMed Corp. was able to prove claims in a Cleveland Medical Devices Inc. sleep apnea patent were invalid, but failed to prove the same on claims in another patent.

  • June 30, 2026

    Investor Sues In Chancery Over Alleged Sham Freeze-Out

    A minority investor in a medical technology company has sued its controlling stockholder in Delaware Chancery Court, accusing him of engineering a sham freeze-out merger that eliminated minority investors for pennies while diverting valuable intellectual property into companies he controlled.

  • June 30, 2026

    ITC Opens Patent Probe Into Chinese Protein Testing Co.

    The U.S. International Trade Commission said it has opened an investigation into a U.S. biotechnology company's claim that a Chinese company is importing and selling kits and other technology in the U.S. that infringe patents related to testing the proteins in genomes.

  • June 30, 2026

    High Court Sends 3 Roundup Cases Back After Monsanto Win

    The U.S. Supreme Court on Tuesday sent back several cases over claims that Bayer unit Monsanto Co.'s Roundup weed killer causes cancer, after the court last week delivered its ruling that state-based claims about a failure to warn on the weedkiller's labeling are barred by federal law.

  • June 29, 2026

    Wash. Panel Revives Claims Over Fertility Operation Injury

    A Washington appeals panel revived two claims against healthcare providers lodged by the family of a woman who suffered permanent brain damage as the result of an allergic reaction during an egg-retrieval procedure, ruling Monday that a lower court was wrong to toss the claims.

  • June 29, 2026

    26 States Sue To Nix Medicaid Work Rule For Medically Frail

    More than two dozen states sued the Trump administration Monday in Massachusetts federal court in a bid to strike down new Medicaid work requirements for certain enrollees, saying the administration did not consider the consequences the requirements would have on vulnerable Medicaid enrollees.

  • June 29, 2026

    AstraZeneca To Pay $34M In Texas Kickbacks Settlement

    AstraZeneca has agreed to pay nearly $34 million to the state of Texas to put to rest allegations the pharmaceutical company gave kickbacks to providers for prescribing its drugs, many of which were covered by the Lone Star State's Medicaid program, according to an announcement made Monday.

  • June 29, 2026

    Hospital That Halted Gender Care Must Show Cause

    A Colorado state court judge issued a citation on Friday to Children's Hospital Colorado ordering it to show cause for why the hospital refuses to provide gender-affirming care to patients in violation of a preliminary injunction order issued by the Colorado Supreme Court. 

  • June 29, 2026

    Sanofi Must Face Labeling Claims In Taxotere Eye Injury MDL

    A Louisiana federal judge won't let Sanofi escape claims in multidistrict litigation that it failed to properly warn about the risks and side effects of its chemotherapy drug Taxotere, saying the label is not so "accurate, clear and unambiguous" that it can be considered adequate as a matter of law.

  • June 29, 2026

    Insulin Makers Can't Nix 340B Antitrust Claims On Remand

    A New York federal judge trimmed proposed class action claims by providers alleging Sanofi-Aventis and other drugmakers colluded to deny them discounts on insulin products under the 340B program, allowing most of their state-law antitrust claims to survive but dismissing their unjust enrichment claims.

  • June 29, 2026

    Juvederm Users Say AbbVie Hid Risks Of Filler

    A putative class action filed in Illinois federal court claims AbbVie failed to adequately warn consumers that its Juvederm hyaluronic acid dermal fillers carry a significant risk of delayed-onset granulomas that can cause painful facial lumps, scarring and disfigurement.

  • June 29, 2026

    Ex-Sales Director Says Fortive Unit Used RIF To Mask Firing

    A former employee of a Fortive medical equipment subsidiary urged a Colorado federal judge to reject the unit and its parent's bid for an early win in her retaliation suit, saying evidence shows a restructuring masked her firing after she challenged government pricing violations.

  • June 29, 2026

    PBMs Drop Fight To Pause Insulin Case Amid Deal Talks

    Optum, Caremark and Express Scripts on Monday dropped their appeal in a case challenging the constitutionality of the Federal Trade Commission's in-house administrative process, and the pharmacy benefit managers are working to settle the commission's remaining insulin-pricing claims.

  • June 29, 2026

    Asthma Drug Developer To Wind Down In Chancery Court

    A subsidiary of Rock Creek Advisors LLC created to administer the liquidation of an asthma drug developer to pay creditors notified Delaware's chancery court that the company turned to a wind-down after clinical trials came to a halt.

  • June 29, 2026

    Supreme Court Shuts Down 4 Patent Cases

    The U.S. Supreme Court turned down four petitions over patent law Monday, meaning it won't review questions related to prosecution laches, jury verdicts, patent eligibility and marking.

  • June 26, 2026

    4 Takeaways From The High Court's Monsanto Ruling

    The U.S. Supreme Court's highly anticipated ruling in favor of Monsanto over its blockbuster pesticide Roundup established that a pesticide's labeling must meet federal standards, ensuring that businesses don't have to comply with a variety of potentially conflicting state laws.

  • June 26, 2026

    PACER Fees Will Rise To Fund Cyber Defense Upgrades

    The federal judiciary announced Friday it will temporarily increase the fees for electronic access to court records to pay for a potential $800 million upgrade that will modernize and strengthen court records systems PACER and CM/ECF, an upgrade it previously said is needed to respond to escalating cyberattacks.

  • June 26, 2026

    Pfizer Beats Ex-Worker's Whistleblower Retaliation Suit

    Pfizer defeated a former employee's whistleblower retaliation suit Friday after a California federal judge ruled the "uncontroverted material facts" show the company would have fired him for "legitimate, independent reasons" even if he did engage in protected whistleblowing.

  • June 26, 2026

    Endoscopy Device Maker's Trade Secret Suit Trimmed In Ohio

    An Ohio federal judge has kept alive most of medical equipment supplier Steris' lawsuit claim that a former research and development director stole its intellectual property to form a competitor, but agreed to trim some claims in the case.

  • June 26, 2026

    DC Circ. Affirms FDA Can Block Norwich's IBS Generic

    The D.C. Circuit on Friday backed the U.S. Food and Drug Administration's lower court win in Norwich Pharmaceuticals' challenge to the agency's refusal to approve an application to bring a generic version of a prescription antibiotic for irritable bowel syndrome to market until 2029.

Expert Analysis

  • 3 AI Adoption Mistakes GCs Should Avoid

    Author Photo

    The pressure in-house legal teams face to quickly adopt artificial intelligence tools, combined with budget constraints and the need to evaluate a crowded market of options, sets the stage for implementation mistakes that are often difficult to undo, says former 23andMe general counsel Guy Chayoun.

  • Series

    Playing Basketball Makes Me A Better Lawyer

    Author Photo

    My grandfather used to say "I wear your jersey" as shorthand for wholly committing to support someone with loyalty and integrity — ideals that have shaped my life on the basketball court and in legal practice, says Tracy Schimelfenig at Schimelfenig Legal.

  • EPA Listing Signals New Scrutiny Of Drugs In Drinking Water

    Author Photo

    The recent publication of the U.S. Environmental Protection Agency's latest draft drinking water contaminant list highlights pharmaceuticals as a category of concern, marking the start of a process that could shape future research priorities, monitoring requirements, and federal and state actions, say attorneys at Morgan Lewis.

  • How Del. Courts Will Likely Evaluate AI Oversight Claims

    Author Photo

    While no Delaware court has thus far adjudicated a claim based on alleged board failures to oversee artificial intelligence risk, recent Court of Chancery decisions suggest that familiar Caremark principles will be applied in predictable but consequential ways, particularly when AI touches mission‑critical operations, say attorneys at WilmerHale.

  • Opinion

    5th Circ.'s Abortion Pill Order Is Shaky On Multiple Grounds

    Author Photo

    The Fifth Circuit's recent order in Louisiana v. U.S. Food and Drug Administration, reinstating an in-person dispensing requirement for the abortion medication mifepristone, seems to turn federalism upside-down, and is also questionable for several other reasons, says Gregory Curtner at Curtner Law.

  • Series

    The Biz Court Digest: Georgia Court Has Business On Its Mind

    Author Photo

    Thanks to recent legislation, the Georgia State-wide Business Court will soon offer business litigants greater access to the court than ever before, further enhancing the court's emphasis on efficiency, predictability and accessibility for sophisticated commercial disputes, says former GSBC judge Walt Davis at Jones Day.

  • Opinion

    USPTO Must Address The Right Question In Sanofi Case

    Author Photo

    The U.S. Patent and Trademark Office Appeals Review Panel's questions in Ex parte Baurin indicate recognition of broader doctrinal issues, but rather than approaching from separate angles, the panel should concentrate on a single fundamental question about obviousness-type double patenting, says Jeremy Lowe at Spencer Fane.

  • 4 Emerging Approaches To AI Protective Order Language

    Author Photo

    Over the last year, at least five federal district courts have issued or analyzed specific protective order provisions restricting the use of generative artificial intelligence platforms with protected materials, establishing that proactive AI-specific provisions are now standard practice and demonstrating that no single model works for every case, says Joel Bush at Kilpatrick.

  • What Justices Are Focusing On In 'Skinny Label' Patent Case

    Author Photo

    Though Hikma v. Amarin appears to be a patent dispute that could reshape inducement doctrine in the pharmaceutical context, oral argument suggests the U.S. Supreme Court may treat this as primarily a pleading-stage dispute, with important unresolved questions lurking beneath the surface, says Shashank Upadhye at Upadhye Tang.

  • Accelerated Psychedelic Therapy Pathways Require Caution

    Author Photo

    President Donald Trump's new executive order aiming to accelerate the approval of psychedelic drugs for the treatment of mental health disorders will likely bolster investigational psychedelic therapies, but parties within the psychedelic product supply chain will still need to prepare for potentially burdensome compliance requirements, say attorneys at Morgan Lewis.

  • Heppner Ruling Left AI Privilege Risk For Lawyers Unresolved

    Author Photo

    While a New York federal judge’s recent ruling in U.S. v. Heppner resolved a privilege question surrounding client-side artificial intelligence use, it did not address how to mitigate the risks that can arise when confidential information enters the operative context of an AI system used by an attorney, says Jianfei Chen at Quarles & Brady​​​​​​​.

  • How 10 Years Of Case Law Have Shaped The DTSA

    Author Photo

    As the Defend Trade Secrets Act reaches its 10th anniversary, attorneys at Ropes & Gray examine recent DTSA case law and highlight key takeaways regarding pleading requirements, damages and risk factors.

  • The Ethics And Practicalities Of Representing AI Agents

    Author Photo

    With autonomous artificial intelligence agents now able to take action without explicit instructions from — or the awareness of — their human owners, the bar must confront whether existing frameworks like informed consent and client privilege will be sufficient on the day an AI agent calls seeking counsel, say attorneys at Morrison Cohen.

  • Series

    Speed Jigsaw Puzzling Makes Me A Better Lawyer

    Author Photo

    My passion for speed puzzling — I can complete a 500-piece jigsaw puzzle in under 50 minutes — has sharpened my legal skills in more ways than one, with both disciplines requiring patience, precision and the ability to keep the bigger picture in mind while working through the details, says Tazia Statucki at Proskauer.

  • Opinion

    Congress Should Ax Privacy Bill For Not Shielding Consumers

    Author Photo

    The SECURE Data Act should be rejected because, despite Congress' claims, it would not meaningfully rein in data practices, but instead would weaken enforcement, eliminate stronger protections and prioritize data extraction over consumer protection and accountability, say attorneys at DiCello Levitt.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.